Pharmaceutical

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer.

Apr 17, 2024 - 00:00
MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Antiverse and GlobalBio extend checkpoint inhibitor collaboration

Antiverse and GlobalBio extend checkpoint inhibitor col...

Oct 17, 2023

The US Biosecure Act threatens to destabilise the pharmaceutical industry 

The US Biosecure Act threatens to destabilise the pharm...

Jul 18, 2024

Opinion: Independent doctors like me are becoming an endangered species

Opinion: Independent doctors like me are becoming an en...

Feb 15, 2024